Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exact Sciences

43.10
+1.523.66%
Post-market: 43.100.00000.00%16:33 EDT
Volume:3.93M
Turnover:168.57M
Market Cap:8.01B
PE:-7.71
High:44.17
Open:41.36
Low:40.80
Close:41.58
Loading ...

Bernstein Reaffirms Their Buy Rating on Exact Sciences (EXAS)

TIPRANKS
·
16 Apr

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

StockStory
·
15 Apr

Tap Into the Silver Economy Boom With These Aging Demographics Stocks

Zacks
·
15 Apr

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

StockStory
·
14 Apr

Exact Sciences Price Target Maintained With a $60.00/Share by Guggenheim

Dow Jones
·
11 Apr

Exact Sciences price target lowered to $55 from $65 at Barclays

TIPRANKS
·
10 Apr

Exact Sciences initiated with an Outperform at Mizuho

TIPRANKS
·
10 Apr

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

StockStory
·
07 Apr

RBC Capital Remains a Hold on Exact Sciences (EXAS)

TIPRANKS
·
03 Apr

Press Release: Exact Sciences Schedules First Quarter 2025 Earnings Call

Dow Jones
·
01 Apr

Exact Sciences announces launch of Cologuard Plus test

TIPRANKS
·
31 Mar

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Business Wire
·
31 Mar

High Growth Tech Stocks To Watch In The US March 2025

Simply Wall St.
·
28 Mar

Should You Retain Exact Sciences Stock in Your Portfolio Now?

Zacks
·
27 Mar

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Zacks
·
21 Mar

1 Healthcare Stock on Our Watchlist and 2 to Turn Down

StockStory
·
20 Mar

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

StockStory
·
20 Mar

BTIG Sticks to Its Buy Rating for Exact Sciences (EXAS)

TIPRANKS
·
18 Mar

BUZZ-RBC initiates Exact Sciences coverage with 'perform' rating on oncology screening strength

Reuters
·
14 Mar

Exact Sciences Initiated at Sector Perform by RBC Capital

Dow Jones
·
13 Mar